Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- Houston Methodist Hospital — Houston, Texas
- Memorial Hermann Texas Medical Center — Houston, Texas
Phase 3 Recruiting Network
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…
Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Texas: - Medical City Dallas Hospital — Dallas, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- El Paso Children's Hospital — El Paso, Texas
- Cook Children's Medical Center — Fort Worth, Texas
Phase 3 Recruiting Industry
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Texas: - USO-Texas Oncology-Central/South Texas — Austin, Texas
- UT Southwestern Medical Center — Dallas, Texas
- US Oncology — The Woodlands, Texas
- USO - Texas Oncology Gulf Coast — Webster, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Texas: - Texas Oncology-Abilene — Abilene, Texas
- Texas Oncology Cancer Center — Austin, Texas
- Jps Health Network — Fort Worth, Texas
- The University of Texas Health Science Center Houston — Houston, Texas
- The University of Texas-Md Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Network
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadj…
Sponsor: GOG Foundation
NCT ID: NCT05659381
Sites in Texas: - Texas Oncology - Central South — Austin, Texas
- Baylor College of Medicine Medical Center — Houston, Texas
- O'Quinn Medical Tower at McNair Campus — Houston, Texas
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Texas: - Texas Oncology - Central/South Texas ( Site 8009) — Austin, Texas
- Texas Oncology - DFW ( Site 8001) — Fort Worth, Texas
- University Of Texas Health Science Center -San Antonio ( Site 0095) — San Antonio, Texas
- Texas Oncology - San Antonio ( Site 8005) — San Antonio, Texas
- Texas Oncology - Gulf Coast ( Site 8003) — Webster, Texas
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Texas: - Texas Oncology Central — Austin, Texas
- Texas Oncology-Fort Worth Cancer Center — Fort Worth, Texas
- Houston Methodist — Houston, Texas
- MD Anderson Cancer Center — Houston, Texas
- Texas Oncology — San Antonio, Texas
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Texas: - Baylor College of Medicine — Houston, Texas
- University of Texas Science Center at Houston, McGovern Medical School — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed o…
Sponsor: AstraZeneca
NCT ID: NCT07816666
Sites in Texas: - Research Site — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in Texas: - Lyndon Baines Johnson General — Houston, Texas
- Houston Methodist — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07776691
Sites in Texas: - Texas Oncology - West Texas ( Site 8009) — Amarillo, Texas
- Texas Oncology - Central/South Texas ( Site 8002) — Austin, Texas
- Texas Oncology - DFW ( Site 8005) — Fort Worth, Texas
- Texas Oncology - Northeast Texas ( Site 8004) — Tyler, Texas
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells gro…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07743164
Sites in Texas: - JPS Oncology and Infusion Center ( Site 0019) — Fort Worth, Texas
Phase 2 Recruiting NIH
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…
Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Texas: - Texas Oncology - Austin Central /ID# 275046 — Austin, Texas
- Texas Oncology - Fort Worth Cancer Center /ID# 275043 — Fort Worth, Texas
- Houston Methodist Hospital /ID# 274568 — Houston, Texas
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090 — San Antonio, Texas
- Texas Oncology - The Woodlands /ID# 275015 — The Woodlands, Texas
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Texas: - Texas Oncology - Central/South Texas — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- University of Texas Southwestern — Dallas, Texas
- Texas Oncology - Northeast Texas — Flower Mound, Texas
Phase 2 Recruiting Industry
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Texas: - Site 0103 - University of Texas MD Anderson Cancer Center — Houston, Texas
- Site 0203 - Texas Oncology — Tyler, Texas
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Texas: - Texas Oncology-Austin Center — Austin, Texas
- Texas Oncology-San Antonio Medical Center Pharmacy — San Antonio, Texas
- Texas Oncology-Tyler — Tyler, Texas
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Texas: - USOR Texas Oncology — Abilene, Texas
- Texas Oncology - Central / South Texas — Austin, Texas
- Mary Crowley Cancer Research — Dallas, Texas
- USOR Texas Oncology — Fort Worth, Texas
- Texas Oncology - Northeast TX — Tyler, Texas
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas: - New Experimental Therapeutics - NEXT Oncology — Austin, Texas
- Texas Oncology — Bedford, Texas
- UT Southwest Simmons Cancer Center — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
Phase 2 Recruiting Industry
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …
Sponsor: AbbVie
NCT ID: NCT07059845
Sites in Texas: - Texas Oncology - Abilene - Antilley Road /ID# 277739 — Abilene, Texas
- University of Texas - Southwestern Medical Center /ID# 278289 — Dallas, Texas
- Texas Oncology - Fort Worth Cancer Center /ID# 277989 — Fort Worth, Texas
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735 — San Antonio, Texas
- Texas Oncology - The Woodlands /ID# 277926 — The Woodlands, Texas
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Texas: - Baylor Scott & White Research Institute — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Baylor Scott & White Medical Center — Temple, Texas
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Texas: - Mary Crowley Cancer Research Center — Dallas, Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- University of Texas Southwestern — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- START San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
A Study of Emi-Le in Participants with Solid Tumors
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05377996
Sites in Texas: - Texas Oncology, P.A. — Dallas, Texas
- MD Anderson — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Texas: - South Texas Accelerated Research Therapeutics — San Antonio, Texas